

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of Security Interest
CONVEYING PARTY DATA	
Name	Execution Date
ALPHARMA, LLC [F/K/A ALPHARMA, INC.]	05/11/2010
RECEIVING PARTY DATA	
Name:	CREDIT SUISSE AG
Street Address:	AS ADMINISTRATIVE AGENT
Internal Address:	11 MADISON AVENUE
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10010
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	12418806
Application Number:	12456300
Application Number:	12435763
Application Number:	12586359
CORRESPONDENCE DATA	
Fax Number:	(800)494-7512
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	800-494-5225
Email:	ecallahan@nationalcorp.com
Correspondent Name:	Elsbeth Callahan
Address Line 1:	National Corporate Research
Address Line 2:	1100 G Street, N.W.
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005
ATTORNEY DOCKET NUMBER:	F126672
NAME OF SUBMITTER:	Mariee Pilkington

OP \$160.00 12418806

501173187

PATENT
REEL: 024370 FRAME: 0014

Total Attachments: 4

source=P Release - Alpharma LLC(10 29 2009)#page1.tif

source=P Release - Alpharma LLC(10 29 2009)#page2.tif

source=P Release - Alpharma LLC(10 29 2009)#page3.tif

source=P Release - Alpharma LLC(10 29 2009)#page4.tif

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)
ALPHARMA, LLC
[F/K/A ALPHARMA, INC.]
Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)
Name: CREDIT SUISSE AG
Internal Address: AS ADMINISTRATIVE AGENT
Street Address: 11 MADISON AVENUE
City: NEW YORK
State: NEW YORK
Country: USA Zip: 10010
Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance/Execution Date(s):
Execution Date(s) MAY 11, 2010
 Assignment Merger
 Security Agreement Change of Name
 Joint Research Agreement
 Government Interest Assignment
 Executive Order 9424, Confirmatory License
 Other Release Security Interest [10/09]

4. Application or patent number(s): This document is being filed together with a new application.
A. Patent Application No.(s)
SEE ATTACHED SCHEDULE
B. Patent No.(s)
SEE ATTACHED SCHEDULE
Additional numbers attached? Yes No

6. Total number of applications and patents involved: _____
7. Total fee (37 CFR 1.21(h) & 3.41) \$ _____
 Authorized to be charged by credit card
 Authorized to be charged to deposit account
 Enclosed
 None required (government interest not affecting title)

5. Name and address to whom correspondence concerning document should be mailed:
Name: Elspeth Callahan
Internal Address: National Corporate Research
Street Address: 1100 G Street, N.W., Suite 420
City: Washington
State: DC Zip: 20005
Phone Number: 1-800-494-5225
Fax Number: 1-800-494-7512
Email Address: ecallahan@nationalcorp.com

8. Payment Information
a. Credit Card Last 4 Numbers _____
Expiration Date _____
b. Deposit Account Number _____
Authorized User Name _____

9. Signature: Mariee Pilkington MAY 11, 2010
Signature Date
Mariee Pilkington
Name of Person Signing
Total number of pages including cover sheet, attachments, and documents: 4

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

Release of Security Interest in Patents

May 11, 2010

WHEREAS, King Pharmaceuticals, Inc., certain of its subsidiaries and Credit Suisse AG, Cayman Islands Branch (formerly Credit Suisse, Cayman Islands Branch) ("**Credit Suisse**"), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the "**GCA**") dated December 29, 2008;

WHEREAS, pursuant to the GCA, Credit Suisse and Alpharma, LLC (formerly Alpharma Inc.) (the "**Assignee**") entered into that certain Patent Security Agreement dated October 29, 2009 and recorded with the United States Patent and Trademark Office on November 4, 2009 on Reel No. 023470, Frame 0144 (the "**Patent Security Agreement**");

WHEREAS, under the Patent Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Patent Collateral (as defined in the Patent Security Agreement), including items those set forth on Schedule 1 hereto (the "**Released Patent Collateral**"); and

WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Patent Security Agreement in the Released Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Patent Security Agreement in the Released Patent Collateral and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee, without any representation or warranty by, or recourse to, Credit Suisse, all right, title and interest of Credit Suisse in, to and under such Released Patent Collateral granted under the Patent Security Agreement. This Release of Security Interest in Patents shall be binding upon Credit Suisse's legal representatives, assigns and successors and upon the Secured Parties. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Patents against the Released Patent Collateral.

[signature page to follow]

Alpharma, LLC (formerly Alpharma Inc.)

PATENTS AND DESIGN PATENTS

None.

PATENT APPLICATIONS

Case #	Serial #	Country	Date	Filing Title
N/A	12/418,806	United States	4/6/2009	Sustained Release Opioid Formulations and Methods of Use
N/A	12/456,300	United States	6/15/2009	Laidlomycin Compositions and Methods
N/A	12/435,763	United States	5/5/2009	Nasopharyngeal Inoculate of Probiotics and Prebiotics for Treatment of Respiratory Infections
N/A	12/586,359	United States	9/21/2009	Compositions and Methods for Controlling Diseases in Animals

PATENT LICENSES

None.